Ranasinghe, D.* ; Lin, W.Y.* ; Fordham, S.E.* ; Alharbi, A.A.* ; Sunter, N.J.* ; Elstob, C.* ; Nahari, M.H.* ; Xu, Y.* ; Park, C.* ; Hungate, E.* ; Quante, A.* ; Strauch, K.* ; Gieger, C. ; Skol, A.D.* ; Rahman, T.* ; Sucheston-Campbell, L.* ; Hahn, T.* ; Clay-Gilmour, A.I.* ; Jones, G.L.* ; Marr, H.J.* ; Jackson, G.H.* ; Menne, T.* ; Collin, M.* ; Ivey, A.* ; Hills, R.K.* ; Burnett, A.K.* ; Russell, N.H.* ; Fitzgibbon, J.* ; Larson, R.A.* ; Le Beau, M.M.* ; Stock, W.* ; Heidenreich, O.* ; Enshaei, A.* ; Gunasinghe, D.* ; Hawking, Z.L.* ; Heslop, H.S.* ; Nandana, D.* ; Di, B.* ; Plokhuta, A.* ; Brown, I.T.* ; Allsup, D.J.* ; Houlston, R.S.* ; Collins, A.* ; Milne, P.* ; Norden, J.* ; Dickinson, A.M.* ; Lendrem, B.C.* ; Daly, A.K.* ; Palm, L.* ; Piechocki, K.* ; Jeffries, S.* ; Bornhäuser, M.* ; Röllig, C.* ; Altmann, H.* ; Ruhnke, L.* ; Kunadt, D.* ; Wagenführ, L.* ; Cordell, H.J.* ; Darlay, R.* ; Andersen, M.K.* ; Fontana, M.C.* ; Martinelli, G.* ; Marconi, G.* ; Sanz, M.* ; Cervera, J.* ; Gomez-Segui, I.* ; Cluzeau, T.* ; Moreilhon, C.* ; Raynaud, S.* ; Sill, H.* ; Voso, M.T.* ; Dombret, H.* ; Cheok, M.H.* ; Preudhomme, C.* ; Gale, R.E.* ; Linch, D.C.* ; Weisinger, J.* ; Masszi, A.* ; Nowak, D.* ; Hofmann, W.K.* ; Gilkes, A.F.* ; Porkka, K.* ; Milosevic Feenstra, J.D.* ; Kralovics, R.* ; Wang, J.* ; Meggendorfer, M.* ; Haferlach, T.* ; Krizsán, S.* ; Bödör, C.* ; Parkin, B.L.* ; Malek, S.N.* ; Stölzel, F.* ; Onel, K.* ; Allan, J.M.*
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
Blood 147, 1958-1969 (2026)
Acute myeloid leukemia (AML) is a complex hematological malignancy with multiple disease sub-groups defined by somatic mutations and heterogeneous outcomes. Although genome-wide association studies (GWAS) have identified a small number of common genetic variants influencing AML risk, the heritable component of this disease outside of familial susceptibility remains largely undefined. Here we perform a meta-analysis of four published GWAS plus two new GWAS, totalling 4710 AML cases and 12938 controls. We identify a new genome-wide significant risk locus for pan-AML at 2p23.3 (rs4665765; P=1.35x10-8; EFR3B, POMC, DNMT3A, DNAJC27) which also significantly associates with patient survival (P=6.09x10-3). Our analysis also identifies three new genome-wide significant risk loci for disease sub-groups, including AML with deletions of chromosome 5 and/or 7 at 1q23.3 (rs12078864; P=7.0x10-10; DUSP23) and cytogenetically complex AML at 2q33.3 (rs12988876; P=3.28x10-8; PARD3B) and 2p21 (rs79918355; P=1.60x10-9; EPCAM). We also investigated loci previously associated with risk of clonal hematopoiesis (CH) or clonal hematopoiesis of indeterminate potential (CHIP) and identified several variants associated with risk of AML. Our results further inform on AML etiology and demonstrate the existence of disease sub-group specific risk loci.
Altmetric
Additional Metrics?
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Myeloid Leukemia ; Locus (genetics) ; Leukemia ; Genome-wide Association Study ; Disease ; Myeloid ; Haematopoiesis ; Malignancy ; Myelodysplastic Syndromes; Coagulation-factor Deficiency; Clonal Hematopoiesis; Survival; Mutations; Aml; Susceptibility; Consolidation; Expression; Complex; Dnmt3a
Keywords plus
ISSN (print) / ISBN
0006-4971
e-ISSN
1528-0020
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 147,
Issue: 17,
Pages: 1958-1969
Article Number: ,
Supplement: ,
Series
Publisher
American Society of Hematology
Publishing Place
Radarweg 29, 1043 Nx Amsterdam, Netherlands
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Institute of Epidemiology (EPI)
Grants
Medical Research Council DiMeN Doctoral Training Programme
Blood Cancer UK
Copyright